Nancy M. Crowell has joined the board of directors of Cell Genesys (Foster City, CA). Ms. Crowell currently serves as a founding partner of Applied Genomic Technology Capital Funds, and was previously the founder and head of health care investment banking at Cowen and Company.

ArQule (Woburn, MA) has elected Ariel Elia to its board of directors, replacing Stephen Dow, who resigned in September. Mr. Elia spent 17 years at Merck & Co., rising to the position of senior vice president, international division, and most recently served as CEO of Jouveinal Laboratories, a privately owned pharmaceutical company.

Duramed Pharmaceuticals (Cincinnati, OH) has announced the appointment of David J. Furniss as senior vice president, corporate planning, a newly formalized position. Mr. Furniss has been with Duramed since 1992, serving previously as vice president, corporate controller.

Dennis W. Genge has been named vice president, chief financial officer/treasurer of Novavax (Columbia, MD). Mr. Genge joins the company from Pyxis, where he served most recently as vice president and controller.

Andrew W. Gengos has been named to the position of vice president and chief financial officer of Dynavax Technologies (Berkeley, CA). He joins the company from Chiron, where he served as vice president of strategy and vice president of corporate development since 1999.

Bradford S. Goodwin has been elected to the board of directors of R&D Logic (San Mateo, CA). He was previously vice president of finance at Genentech, and is currently the president, COO, and founder of iO Pharmaceuticals.

R. Scott Greer and Peter Barton Hutt have been named to the board of directors of CV Therapeutics (Palo Alto, CA). Mr. Greer is president, CEO, and chairman of Abgenix, and Mr. Hutt is a partner in the law firm of Covington & Burling.

Uli Hacksell has been appointed chief executive officer of ACADIA Pharmaceuticals (San Diego, CA), replacing Leonard R. Borrmann, who has left to pursue other interests. Dr. Hacksell had previously held the position of executive vice president of drug discovery since joining ACADIA in February 1999 from Astra.

SkyePharma (London) has announced the appointment of Tamar Howson as a non-executive director. Ms. Towson was formerly senior vice president and director of worldwide business development at SmithKline Beecham.

Genaissance Pharmaceuticals (New Haven, CT) has announced the appointment of Kenneth B. Kashkin as executive vice president and chief medical officer. Dr. Kashkin was most recently vice president of clinical development at Knoll Pharmaceutical.

Cellular Genomics (New Haven, CT) has announced the appointment of Louis A. Matis as president, chief scientific officer, and a member of the board of directors. He previously served as senior vice president and CSO of Alexion Pharmaceuticals.

PowderJect Pharmaceuticals (London) has announced the appointment of Gerald Möller as a non-executive director. Dr. Möller was previously CEO of Boehringer Mannheim, and is currently chairman of two German biotechnology companies, MorphoSys and November AG.

B. Lynne Parshall has been elected to Isis Pharmaceuticals' (Carlsbad, CA) board of directors, increasing its number to seven. Ms. Parshall, currently executive vice president and CFO of Isis, joined the company in 1991 as vice president and general counsel.

The Immune Response Corp. (Carlsbad, CA) has elected Alan S. Rosenthal to its board of directors. Dr. Rosenthal most recently served as the vice president of scientific affairs and technology at Abbott Laboratories.

Paradigm Genetics (Research Triangle Park, NC) president and CEO John Ryals has been appointed to the Biotechnology Industry Organization (BIO) executive committee, BIO board of directors, and the newly established BIO Food and Agriculture Governing Body for the 2000–2001 term. Dr. Ryals, the former vice president of research at Novartis Crop Protection and head of Novartis' Biotechnology and Genomics Center in Research Triangle Park, co-founded Paradigm Genetics in 1997.

Deni M. Zodda has been named senior vice president, business development of Discovery Laboratories (Doylestown, PA). He joins the company from KPMG, where he was managing director and group head of the corporate finance–life sciences practice.